124 related articles for article (PubMed ID: 34403526)
21. LMNA-NTRK1 rearranged mesenchymal tumor (lipofibromatosis-like neural tumor) mimicking pigmented dermatofibrosarcoma protuberans.
Panse G; Reisenbichler E; Snuderl M; Wang WL; Laskin W; Jour G
J Cutan Pathol; 2021 Feb; 48(2):290-294. PubMed ID: 32519338
[TBL] [Abstract][Full Text] [Related]
22. NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities.
Nozzoli F; Lazar AJ; Castiglione F; Campanacci DA; Beltrami G; De Logu F; Caporalini C; Massi D; Roviello G
Pathol Oncol Res; 2022; 28():1610237. PubMed ID: 35295613
[TBL] [Abstract][Full Text] [Related]
23. Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria.
Antonescu CR
Genes Chromosomes Cancer; 2020 Aug; 59(8):437-444. PubMed ID: 32243019
[TBL] [Abstract][Full Text] [Related]
24. Cytomorphologic features of NTRK-rearranged thyroid carcinoma.
Viswanathan K; Chu YH; Faquin WC; Sadow PM
Cancer Cytopathol; 2020 Nov; 128(11):812-827. PubMed ID: 33074583
[TBL] [Abstract][Full Text] [Related]
25. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
26. Identification of NTRK fusions in pediatric mesenchymal tumors.
Pavlick D; Schrock AB; Malicki D; Stephens PJ; Kuo DJ; Ahn H; Turpin B; Allen JM; Rosenzweig M; Badizadegan K; Ross JS; Miller VA; Wong V; Ali SM
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28097808
[TBL] [Abstract][Full Text] [Related]
27. Infantile NTRK-associated Mesenchymal Tumors.
Davis JL; Lockwood CM; Albert CM; Tsuchiya K; Hawkins DS; Rudzinski ER
Pediatr Dev Pathol; 2018; 21(1):68-78. PubMed ID: 28683589
[TBL] [Abstract][Full Text] [Related]
28. NTRK-rearranged Cervical Sarcoma: Expanding the Clinicopathologic Spectrum.
Hodgson A; Pun C; Djordjevic B; Turashvili G
Int J Gynecol Pathol; 2021 Jan; 40(1):73-77. PubMed ID: 32044823
[TBL] [Abstract][Full Text] [Related]
29. STRN-NTRK3-rearranged Mesenchymal Tumor of the Uterus: Expanding the Morphologic Spectrum of Tumors With NTRK Fusions.
Michal M; Hájková V; Skálová A; Michal M
Am J Surg Pathol; 2019 Aug; 43(8):1152-1154. PubMed ID: 31107720
[No Abstract] [Full Text] [Related]
30. NTRK fusions are extremely rare in bone tumours.
Lam SW; Briaire-de Bruijn IH; van Wezel T; Cleven AHG; Hogendoorn PCW; Cleton-Jansen AM; Bovée JVMG
Histopathology; 2021 Nov; 79(5):880-885. PubMed ID: 34148257
[TBL] [Abstract][Full Text] [Related]
31. [Detection and clinical significance of NTRK in digestive system neoplasms].
Hou XJ; Fu Y; Pu XH; Fan XS
Zhonghua Bing Li Xue Za Zhi; 2023 Aug; 52(8):876-880. PubMed ID: 37528002
[TBL] [Abstract][Full Text] [Related]
32. Why will there never be a randomized trial for NTRK-rearranged tumors?
Penel N; Lebellec L; Blay JY
Ann Oncol; 2023 Jul; 34(7):626-628. PubMed ID: 37068657
[No Abstract] [Full Text] [Related]
33. Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.
Saleh K; Felefly T; Khalife N; Kourie HR
Pharmacogenomics; 2021 Apr; 22(5):247-250. PubMed ID: 33754802
[No Abstract] [Full Text] [Related]
34. Fine-needle aspiration cytomorphology of papillary thyroid carcinoma with NTRK gene rearrangement from a case series with predominantly indeterminate cytology.
Abi-Raad R; Prasad ML; Adeniran AJ; Cai G
Cancer Cytopathol; 2020 Nov; 128(11):803-811. PubMed ID: 32931153
[TBL] [Abstract][Full Text] [Related]
35. [NTRK fusion gene expression in solid tumors and research progress of Trk small molecule inhibitors].
Yue JQ; Cai L; Li JL; Guan WB; Wang RF; Yu WW; Wang LF
Zhonghua Bing Li Xue Za Zhi; 2020 Sep; 49(9):972-976. PubMed ID: 32892574
[TBL] [Abstract][Full Text] [Related]
36. A rare case of spindle cell neoplasm with NTRK-fusion in central nervous system.
Gong H; Gao K; Mao P; Ma S; Zhao D; Bian Y; Liu R; Gao L; Duan Q; Zhang Q; Tan Y; Wang T
Pathol Int; 2023 Jan; 73(1):52-54. PubMed ID: 35900013
[No Abstract] [Full Text] [Related]
37. The oncogenic roles of NTRK fusions and methods of molecular diagnosis.
Aref-Eshghi E; Lin F; Li MM; Zhong Y
Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798
[TBL] [Abstract][Full Text] [Related]
38. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
39. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
40. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
